TABLE 2.
Opportunity areas | Mechanisms causing bleeding | Innate immunity and thrombosis | Venous thrombosis |
---|---|---|---|
Assessing and visualizing hemostasis | ✓ | ✓ | ✓ |
Blood rheology‐driven vascular effects | ✓ | ✓ | |
Cancer‐associated thrombosis | ✓ | ||
Cellular contributions to thrombosis and hemostasis | ✓ | ✓ | ✓ |
Major hemorrhage | ✓ | ||
Obesity‐related thrombotic complications | ✓ | ✓ | |
Pathogen‐induced effects (e.g., COVID−19, sepsis, etc.) | ✓ | ✓ | ✓ |
Platelet production and function | ✓ | ||
Rare bleeding diseases | ✓ | ||
Rare thrombotic diseases | ✓ | ✓ | |
Safe anticoagulants | ✓ | ✓ | ✓ |
Structure‐function of hemostatic proteins | ✓ | ✓ | ✓ |
Trauma‐induced coagulopathy | ✓ | ✓ | |
Universal prohemostatics | ✓ | ✓ |
Fourteen opportunity areas were identified and subsequently organized into three overarching categories that umbrella many of the various topics.